Improving the safety of platelet transfusions by UV-C: Let's go back to the bench.
作者信息
Prati Daniele
机构信息
Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.
出版信息
Haematologica. 2021 Apr 1;106(4):926-927. doi: 10.3324/haematol.2020.275156.
Abstract
摘要
相似文献
1
Improving the safety of platelet transfusions by UV-C: Let's go back to the bench.
Haematologica. 2021 Apr 1;106(4):926-927. doi: 10.3324/haematol.2020.275156.
2
Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Lancet. 2002 Jun 22;359(9324):2145-52. doi: 10.1016/S0140-6736(02)09090-6.
3
A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
Cancer. 1988 Aug 15;62(4):795-801. doi: 10.1002/1097-0142(19880815)62:4<795::aid-cncr2820620426>3.0.co;2-7.
4
Platelet transfusions: treatment options for hemorrhage secondary to thrombocytopenia.
J Vet Emerg Crit Care (San Antonio). 2012 Feb;22(1):73-80. doi: 10.1111/j.1476-4431.2011.00706.x.
5
Neonatal Platelet Transfusions and Future Areas of Research.
Transfus Med Rev. 2016 Oct;30(4):183-8. doi: 10.1016/j.tmrv.2016.05.009. Epub 2016 May 27.
6
Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia.
J Clin Invest. 1959 Oct;38(10 Pt 1-2):1689-97. doi: 10.1172/JCI103947.
7
Transfusions of suspensions of blood platelets in thrombocytopenia and thrombopathia.
J Clin Pathol. 1953 Feb;6(1):41-5. doi: 10.1136/jcp.6.1.41.
8
POLYMORPHISM OF COLLECTION, TRANSFUSION AND EFFECTIVENESS OF DONOR PLATELETS CONCENTRATES.
Anesteziol Reanimatol. 2017 Jan;62(1):77-79.
9
TREATMENT OF THROMBOCYTOPENIC PATIENTS WITH REPEATED PLATELET TRANSFUSIONS.
Rev Belg Pathol Med Exp. 1965 Apr;31:139-45.
10
Platelets Structure, Function and Modulator Capacity in Replacement Therapy.
Cardiovasc Hematol Disord Drug Targets. 2017;17(3):180-184. doi: 10.2174/1871529X18666171227152937.
本文引用的文献
1
Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial.
Haematologica. 2021 Apr 1;106(4):1086-1096. doi: 10.3324/haematol.2020.260430.
2
Effects of the COVID-19 pandemic on supply and use of blood for transfusion.
Lancet Haematol. 2020 Oct;7(10):e756-e764. doi: 10.1016/S2352-3026(20)30186-1. Epub 2020 Jul 3.
3
Revisiting study design and methodology for pathogen reduced platelet transfusions: a round table discussion.
Transfusion. 2020 Jul;60(7):1604-1611. doi: 10.1111/trf.15779. Epub 2020 May 6.
4
A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets.
Transfusion. 2020 Jun;60(6):1267-1277. doi: 10.1111/trf.15791. Epub 2020 Apr 23.
5
The long and winding road to pathogen reduction of platelets, red blood cells and whole blood.
Br J Haematol. 2019 Sep;186(5):655-667. doi: 10.1111/bjh.16093. Epub 2019 Jul 14.
6
Challenges in the Design and Interpretation of Noninferiority Trials.
N Engl J Med. 2017 Oct 5;377(14):1357-1367. doi: 10.1056/NEJMra1510063.
7
Pathogen-reduced platelets for the prevention of bleeding.
Cochrane Database Syst Rev. 2017 Jul 30;7(7):CD009072. doi: 10.1002/14651858.CD009072.pub3.
8
Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.
Transfusion. 2017 May;57(5):1171-1183. doi: 10.1111/trf.14042. Epub 2017 Feb 24.
9
The Primary Outcome Fails - What Next?
N Engl J Med. 2016 Sep 1;375(9):861-70. doi: 10.1056/NEJMra1510064.
Zotero 插件